MetaCap

Insulet (PODD) vs ResMed (RMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ResMed (RMD) has outperformed Insulet (PODD) over the past year, losing 6.0% versus a loss of 59.8%. Over five years, RMD leads with a -6.2% price change compared with -54.9% for PODD. ResMed is the larger company by market cap ($33.14 billion vs $9.24 billion), about 3.6 times the size, while Insulet is growing revenue faster (+30.7% vs +9.9%).

On valuation, Insulet trades at a lower forward P/E (16.8x vs 17.8x for ResMed). ResMed pays a dividend yielding 1.04%, while Insulet does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 9.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PODD-59.79%RMD-6.03%
+14%-25%-64%
Nov 21, 20251 yearNov 20, 2026
PODD-55.76%RMD-9.48%
+19%-20%-60%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PODD versus RMD key metrics
MetricPODDRMD
Share price$133.17$235.63
Market cap$9.24B$33.14B
1-day change-2.96%-0.53%
YTD return-53.15%-2.18%
1-year return-59.79%-6.03%
5-year return-54.92%-6.20%
P/E ratio (TTM)21.7621.46
Forward P/E16.8317.82
EPS (TTM)$6.12$10.98
Dividend yield0.00%1.04%
Annual dividend$0.00$2.46
Revenue (latest FY)$2.71B$5.65B
Revenue growth (YoY)+30.73%+9.85%
Net income (latest FY)$247.10M$1.52B
Gross margin71.63%61.06%
Operating margin17.50%33.37%
Net margin9.12%26.94%
52-week high$342.13$277.67
52-week low$126.40$180.27
Distance from 52-week high-61.08%-15.14%
Analyst consensusbuybuy
Avg. price target upside+33.60%+12.18%
Average volume1.61M1.30M
Shares outstanding69.37M140.66M
Employees5,40011,370
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ResMed is about 3.6 times larger than Insulet by market value ($33.14B vs $9.24B).
  • RMD has outperformed PODD by 53.8 percentage points over the past year.
  • ResMed offers a meaningfully higher dividend yield (1.04% vs 0.00%).
  • ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
  • Insulet grew revenue faster in its latest fiscal year (+30.73% vs +9.85%).

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

About ResMed

RMD stock →

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.

Health Care · Medical/Dental Instruments · 11,370 employees

PODD vs RMD FAQ

Which is bigger, Insulet or ResMed?

ResMed (RMD) is larger, with a market capitalization of $33.14B compared with $9.24B for Insulet (PODD).

Which stock has performed better over the past year, PODD or RMD?

RMD returned -6.03% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PODD or RMD?

RMD has the lower trailing P/E at 21.5, versus 21.8 for PODD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Insulet or ResMed?

ResMed pays a dividend yielding 1.04%, while Insulet does not currently pay a regular dividend.

Are Insulet and ResMed in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons